PK and DDI of Cetuximab and Carboplatin in Advanced Solid Tumors

Phase 2, open-label trial of KL-140 in solid tumor (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Total Carboplatin Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]), Cetuximab PK: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC τ,ss) and 5 more. Started Jun 2010; status: completed.